Said in CommitteeBeta

Exactly as spoken.

ALC - State Insurance Programs Oversight Subcommittee

November 18, 2026 ·11:00 AM ·Room A, MAC ·43:59
Video Transcript 4 documents

Summary

Machine transcript

May contain errors. Verify important quotations against the official video.

About transcript accuracy
Source
SliQ live captions
Model
SliQ live ASR
Processing date
November 18, 2026

B. Consideration for Review and Approval of Actions by the State Board of Finance 0:23

The chair, Grant Wallace, presented a comprehensive set of September 2026 pharmacy formulary changes-including brand-to-generic switches, removal of prior-authorizations for members ≤ 25, addition of a new biosimilar, and exclusions for several high-cost or weight-loss drugs-covering items 1 through 24 and related notes on step-therapy and new market drugs.

Committee members questioned age-based authorization rules, grandfathering periods, and the safety and cost implications of self-administered high-price injections, leading Chair Petty to call for a motion to approve the pharmacy recommendations, which passed unanimously on an aye vote.

Subsequent motions to approve Exhibit B items were made, with Senator Irvin moving to adopt B1 (Sept 2026) and a modified B2 excluding items 7-9, and later a motion to adopt the medical drug recommendations (B3); both motions were seconded, passed without opposition, and recorded as approved.

C. Other Business 35:19

Senator Hickey raised concerns about the lack of cost caps for very expensive self-administered drugs and suggested limits, while the chair explained that the plan follows FDA guidance rather than set financial caps; other senators discussed pill-count controls and waste prevention, resulting in a substantive policy-focused discussion but no formal motion or vote.

Official video page ↗

Transcript

Transcript available SliQ live captions ✓ Whisper ✓ Download .txt
Machine transcript

May contain errors. Verify important quotations against the official video.

About transcript accuracy
Source
SliQ live captions
Model
SliQ live ASR
Processing date
November 18, 2026
the first item of business, Mr. Wallace if you want to come to the table first items of the business are the September 2026 EBD pharmacy recommendations Good morning Grant Wallace,
▶ Play
director of the employee benefits division and officefice of Property Risk so we'll start with the September 2026 pharmacy formulary recommendations items 1 through6 we are making a change from the brand over to the generic items7,8 and 9 we are just removing the prior authorization requirements for members who are 25 years and younger those that are over 25 will still need to complete an appeal with the plan for coverage Item10 we are moving from not covering the pack but still have the tablet formulation available for our members itemtem11 and 12 we are moving to align to the lower strength availability and 12 where we have other lower cost alternatives that are available I'd 13 is a new biosimilar that is coming on so we're adding that to the formulary items 14 and 15 we are not covering because we already have lower cost generics available on our item or on our formulary item 16 through 18 we're moving from requiring a prior authorization to just adapting to a step therapy so what this would mean is that you would just have to take a a generic form or some other form before you step up to these particular medications Item19 is covering we cover the generic tablets already so we're not gonna we're moving away from that one of the capsule item 20 is a new FDA formulation for lidocaine jelly that we are adding. items 21 through 23 are new to market drugs that we are not ready to add to the formulary as we await further studies itemtem24 is a an exclusion because this is for weight loss only at this time items 25 through 28 are new to markets that we are not covering until we wait further studies and then 29 is this is a new to market drug that treats pancreatic cancer that has shown significant improvements and overall survival and quality of life so we're looking to add that on to our formulary at this time that'll be glad to pause there and answer any questions all right members you've heard the recommendation do you have
▶ Play
any questions do you have any questions looks like we do all right Senator Boyd, you're recognized thank you Mister Chair.
▶ Play
Mr. Wallace just think I know the answer but on number 15 albuterol HFA inhaler what what is the change there so this
▶ Play
one we do have lower costs but I think this was a manufactured there was a manufacturer change with this particular formulations so that's why we're removing it. OK. thank you right, Senator hickey you
▶ Play
had a question yes and I just,
▶ Play
I guess I want to understand this better on7,89 where we've got this age in there and obviously it looks like for acne which I assume that's a difference but I guess my my question is do we have other drugs where we have certain ages involved there's a variety for a variety
▶ Play
Speaker 22 5:15
of reasons variety of different ages it really is depending
▶ Play
upon what's being treated a lot of it comes down to whether you take a tablet or like a a liquid we do a lot of age restrictions on that just for swallowing and things like that so but what we've got you said tell me tell me again did you say you have to have like prior approval if you're over 25 so
▶ Play
Speaker 24 5:36
if you're over 25 you would have to appeal to
▶ Play
the plan to be able to get this drug covered. Is there small label
▶ Play
uses or something with these is that is that cosmetic is that's what's going on there's
▶ Play
Speaker 27 5:51
some cosmetic purpose use uses so yes OKok and we wouldn't approve like a cosmetic not for cosmetic purposes think that makes sense thank you sir thank you Representative ladyman you're recognized thank you Mr Chairman. I'm
▶ Play
over here I just had a question in the
▶ Play
impacted members there where it talks about grandfathering so people are already on that if it says lifetime then they would have a lifetime grandfather ability and then a couple of them are 90 days why why is there a difference in that so generally for
▶ Play
specifically like the 90 days if we're moving from a brand to a generic, we do want to give time to have the appropriate visits to the prescribing provider those kind of things to make that transition in other areas where we kind of know that the members that are currently on it are within that particular age range for example there's no reason to disrupt them we would let that continue on until obviously they reached over the age and then others it u it's we're trying to make a move like if we shift to a biosimilar we're ok with kind of capsulating one particular group and then try to make the new fills go on to either the new generic or the new biosimilar we try to be as least disruptive to the care as possible but at the end of the day we are trying to manage the spend and and make the appropriate decisions in that way as well right thank you right members seeing
▶ Play
no others I would entertain a motion for approval of recommendation have a motion and a second all those in favor let it be known by I. any opposed motion carries
▶ Play
Speaker 36 7:47
all right Mr. Wallace, you can carry on to October. OK?
▶ Play
October line number one this is the bestrey pen. it's a new self-administrative version of this particular medication. we already cover this medication on the medical form ul ary we're just adding this option to the pharmacy formulary just to have additional options for treatment item 2 we already cover this is a noodle market we already have lower cost alternatives available so we're not covering it at this time. Item3 is a new combination for treatment so we are adding that just to make sure we have a a good variety of treatment options for that disease condition. itemtems4,5 and6 we're adding these back to the formulary just due to shortages of other products within this disease state so just making sure that we don't run into any treatment issues because of that shortage Ite se,8 and 9 we are moving these to not covered because we already have lower cost generics available as we kind of did an evaluation of what we cover itemtem10 and 11 we are updating the quantity limits just to match to manufacturing package changes so we didn't want to run into any issues with getting those approved item 12 is no longer manufactured so we're removing that from the formulary items 13 through 21 we are moving from the medical benefit to add to the pharmacy benefit and this is just aligning with giving providers flexibility and treatment. this is often called white bagging where the patient would be able to go and work with their provider to get the drugs delivered to the provider's office for administration in that clinical setting I'd be glad to answer any questions Senator Boyd you're recognized thank you chairir. So
▶ Play
Mr Wallace correct me if I'm wrong but I believe you said the first one and the last one are ones that are covered me by the medical benefit but you're gonna allow the pharmacy benefit to cover them as well correct OK I just want to verify before we shift that is this a situation where the plan's just not paying enough so we're hoping that pharmacy will eat the cost rather than somebody else no no this is needed to confirm is you weren't just trying to shift the problem elsewhere. sir thank you So so back with with that number one so are
▶ Play
are we saying that the pharmacy then that these people can they can just come in on their own and they're going to get this an administster it at their house so it's $10,421 per injection they break their they break their vowal or whatever at the house who's who's that on is that how does
▶ Play
Speaker 45 11:05
that work so that's where they would come and appeal and get an early
▶ Play
refill But again this there are prior authorizations with this it is at our highest tier so I mean they're there's a appropriate cost sharing there some of those that gets a little
▶ Play
bit worrisome don't get me wrong I want the patients to you know have all the benefit they can it's just we start getting into things like that that that does start worrying me a little bit. No absolutely and
▶ Play
it's kind of the same when you look at oral chemotherapies. I mean dropping one pill losing one pill can be multiple thousands of dollars so I think there's some fine line that you want to balance to make sure that the member adheres to treatment and that we're giving them all the options available to that treatment but at the same time knowing that there's great responsibility that comes with those medications and making sure that the appropriate provider followups and those kind of things are taking place to make sure that that that adherence is being maintained let me ask you one other thing so if we if we had if
▶ Play
we had one of our members one of the patients whatever you wanna call it if we had one of them that started having like multiple issues with like a $10,000 injection if they had 12 or three. do we have an avenue so that we do have an avenue so that we could not allow that back through the pharmacy OK yes
▶ Play
we and and we work with our our pbm to monitor those make sure that there's no abuse or misuse or anything like that and just to follow
▶ Play
up on senator hickey's question there so this this particular treatment is what we're doing here is allowing us to after it has been authorized at the at the medical level to just then go fill it at the pharmacy it's not like I can wake up one day and decide that I want to do that it's through a treatment plan that the pharmacy ok absolutely so the initial any of the initials on these are
▶ Play
done within the clinical setting it would be the subsequent if those are available subsequent dosage would be done in a home setting self- administered type setting thank you
▶ Play
for that clarification let's see Senator Clark looks like you need a haircut or actually
▶ Play
that's senator Irving so you're recognized thank you Senator Petty. thank you. Explain to me on exhibit B2 why the contraceptive and the maintenance of pregnancies are not covered so on that
▶ Play
particular contraceptive we have multiple that we do cover this was just anuodle market that we were waiting for kind of further didn't really see kind of a a huge groundswell of adding it at this point that's not to say later on down the road we want to you know swap out some and add it we definitely can. We just felt that we have an appropriate amount that are already covered and and didn't want to add that at this point and similar to the maintenance of pregnancies we do have a complete evaluation of what we cover and these we just felt we had lower costs va options available that met the need at this point but we we will continue to evaluate this worries me. I'll be honest with you
▶ Play
because what I what I see I know that I think it was senator Bryant had a a piece of legislation that just basically as we are kind of moving down this path of legislation that requires you know, certain things but then insurance won't pay for it and but we're not keeping up with the technology and the effectiveness of maybe something that's new that's come on the market that's really because if this is you know, maintenance of pregnancy this is important stuff. I mean we don't want to lose a baby we don't want to have we don't want to contribute to maternal deaths or premature babies that creates an incredible amount of expense on the back end if you have a premature baby that ends up in the NICU and so this gives me a little bit of pause to be frank with you and I don't want us to have to pass legislation in order to get women what they need, that's that's really going to be effective and we've had to have that before you know we we kind of get in this mindset as from an insurance that well we're paying for a wheelchair. well yeah it was built in 1950 and that's the only one we'll pay for you know a wooden wheelchair. Well I think things have changed a little bit. there's some modernization here so you know those those things just kind of create a little bit of anxiety for me. No, I totally appreciate and understand that and just try to get a little bit more information to make sure that we have something there that's that's and and I know we do have
▶ Play
stuff that's covered that is effective and I know that we're we're in that process of that evaluation and and we're constantly wanting to make sure we're getting the most effective treatment that we are managing costs at the same time and forgive me I don't know exactly if there was kind of a a a manufacturing change or we were preferring one kind of particular maintenance drug over another. I can follow up and get you that additional information but definitely I I do hear what you're saying and and we do take that to heart and are kind of monitoring and making sure that we are making sure we have enough options available but also that we are getting effective drugs on the formulary OK because cost
▶ Play
doesn't doesn't seem to be that big
▶ Play
issue with this particular in this state
▶ Play
they would not be one more question too do you have the ability to limit pill count on high cost medications. OK. I think that's important. OK. and then the last question I have is uh, anything as it relates to obesity and treatment of obesity is that based on just the product itself or is there some sort of an exclusion that we have had that it's not considered essential health benefit therefore we're not going to treat it. So at this time
▶ Play
the plan excludes weight loss medications as whole on the on the whole now obviously with kind of Ozempic Majaro the type two diabetes diabetes diagnosis and that is where those particular drugs are used to treat those disease states I I think we are studying we're evaluating and we're trying to figure out the best way those drugs are very expensive and and do come at a a high cost for the plan so it's it's a hard balance and I I think you'll see hopefully between now and the session that we're looking at doing lots of different things in order to kind of encourage healthy lifestyles within our member population and looking at kind of revamping some programs to really be able to work on that and combat that holistically and not just rely on a shot I I've been on the record and and we'll say till I'm blue in the face there's no silver bullet to treating obesity and I want to make sure any offering that we have that is working with that is holistic and that ' re clearly being abused. I mean, you know there's people that really are not obese that are
▶ Play
partaking because anyway that's a whole another conversation. I just wanted to know if it was just how it was considered and if it was ok thank you
▶ Play
thank you and in following up from that Mr. alss would you mind just send to staff kind of what the alternatives are in that class for the the maintenance of pregnancy and and if there's a a wide variation of of insert or or use so if one you have it's5 dollars but you have three times as many you know applications just if they're all relatively the same then you don't have to give that just the the the cost is fine but that would be that would be helpful to follow up with Senator Irvin's question all right senator hickey you have a question you're recognized Yes I keep and I don't have an answer for it. I just I hate to keep harping on
▶ Play
it but and there's a whole there's a whole bunch of these they used number one first but let's just go to number 21. so that particular one is $17,000 per injection so when we're allowing them to go to the pharmacy and to and to get this and it looks like there's4 injections per month are are we allowed are we allowing them to pick up this thing which would be668,000 dollars cost for us
▶ Play
for a month so the ones that are 13 through 21 are still going to be administered in a clinical setting by a provider. this is just allowing a different kind of reimbursement and and a different access for that patient some providers don't want to stock medications don't want to have to like manage the quote unquote pharmacy benefit so this allows another path for the member to be able to access that but at the end of the day the drug is still being administered in a clinical setting under the purview of a provider perfect on that one. so
▶ Play
let's go back to number one. So and I have no idea. so on on this number 1 $10,421 per injection like how many times a month would that one be I wonder. it's I guess I guess the thing is is I'm I'm looking at it like on your last one that is in a clinical setting. I just, I don't know if this is once a week or if this is every two or three days or we are we dispersing these to go to the house where it's going to be $100,000 a month or something.
▶ Play
Speaker 25 21:46
I'm just so the one I I believe is just every30 days and
▶ Play
that that is the self like I would be able to administer that to myself after I've done the initial treatment and then have been trained on how to do it through with a provider but we are monitoring those so that we're not I mean, I don't know
▶ Play
where there's a where there's a stopping point you know and again, I understand if you're if you've got that problem and you want to be at home but there does get to be a point right there if you let's just use the last one and again you have that in the clinical setting you know if something gets up to a certain amount of money are we looking at it that it still has to be in that clinical setting to be
▶ Play
administered and again it's gonna depend upon the certain drug which one is going where but we are monitoring the spend and we are making sure you know if there's a high costt claim or anything like that that that it is being reviewed and that there are kind of the appropriate stops that there's no early refills or anything like that. Right. just, just point blank so you got you got one
▶ Play
that's 10,000 a month if it's 10,000 a month, maybe that's appropriate you know it's just if they're keeping this in the refrigerator or whatever and you got grandkids or whatever that can get to it. I just assumed that there has to be a point right there. I wouldn't want the68,000 us to ever do something that was68,000 you know that was we didn't have some safeguards in in place because you start talking about68,000 a month for 12 months you start talking about some real money sir and I do want to correct
▶ Play
one thing they're letting me know so the pin is actually 2 times a month so it's dosed every two weeks it says oh ok that's the top one. Yeah, tier
▶ Play
Speaker 81 23:38
four is the specialty tier so that has
▶ Play
the highest copays to it and again that prior authorization does protect the plan that we're making sure that this is an appropriate member that it is in the setting to be able to do this at home OK I think you know where I'm
▶ Play
kind of going with this stuff. It just there looks like to me there has to be at some point, at some point on whenever we're looking at stuff like that it it just has to be at some point I think where we really have to study whether or not we should allow those at home or if it has to be in the clinical setting so ok thank you sir thank you and Senator Irvin they did
▶ Play
give me some additional information on seven and the endometrian that's the name brand so we do have the generics in that one so that that's what's going on there irvin you recognized And generics don't always work great
▶ Play
and they and so everybody is different and so I I really I really would love for us to cover these because it's it doesn't seem like it's a huge amount of cost, but can I just request that y'all really take a strong look at that because a generic it's yeah sometimes that will work but sometimes it won't and so we just I want to make sure that if if a doctor says she needs this and this is going to maintain this pregnancy to create a twoterm delivery then we need to spend the money to do that point blank because preventing a premature birth to me is worth its weight in gold so those those three7,8,9, I would really prefer that we do cover them somehow some way Senator Urbann are you recommending that they be pulled off until
▶ Play
the next Yes I will yes I I do I would the
▶ Play
contraception one I know I understand that one but when we're talking about maintenance of pregnancy issues and endometriosis and and I mean and the progesterone vaginal insert, whatever we've got to give that doctor the tools that they need right then and there to really make sure that we're maintaining that woman's pregnancy to term. that's a very very, very important. So yeah I would pull these three off and have you guys try to really do some more hard look here because I'd love to have them covered and if we need to have a a prior authorization of course we I need to know more about this andd I really would prefer them to be covered. Thank you, Mr Chair. thank you
▶ Play
Senator Irvin. so if you would just that analysis of what all the options are the generics and and other name brands potentially or whatever and and send that to staff and then we can we can address this at the next at the next meeting OK. all right Senator Boyd you're recognized thank you Mr chairir So going
▶ Play
back to number one the beremi just for clarity's sake, would you say that that comes in a a pen which while it could be broken is harder to break than just a regular glass vial. Yes sir thank you sir. And then would you also agree that if the patient is administering it as opposed to taking it to a clinic that might avoid some administration charges that need to be considered in the overall scope of things sir ok thank you for adding clarity you Senator Love, you're recognized
▶ Play
thank you Mr chairir and I
▶ Play
wanna I want to get in on this discussion first of all back to what senator Boy says in regards to suffer mini s t ration no because the conversation was about getting refilled early if a valve a valve breaks or whatever how often does that happen? how often does this occur? Not not very often and and they would
▶ Play
come to us for an exclusion or an override. So I mean it has to be pretty extreme circumstances the ones that I have personally dealt with have been as a result of the winter storm that came through and lost power and the refrigeration went out or some that honestly related
▶ Play
Speaker 15 28:19
to storm damage so is there is there an overall cost or or actually not only is there overall cost
▶ Play
Is there overall yeah, is there an overall cost that that we have each year for incidents like
▶ Play
this I would have to go back and and run that it's not significant to the overall plan spinn I think if I'm kind of going understanding where you're going with the question this is not like a huge aspect of what we're dealing with they're very rare instances where we would authorize an override due to you know, power outage or damage and shipment or something like that. OK all
▶ Play
right thank you and then and then the second thing in regards to what Senator Urvin was was saying because I've actually I personally have not experienced this but I've actually had this experience are are we just looking at those taking off those drugs789 just because we have generic versions or is it a cost saving like like what what are we what's the overall piece that we're trying
▶ Play
to get to it was to kind of the generic which is at a lower cost than in comparison to the name brand but we're going to go back to that overall study and and bring it back to you all at
▶ Play
a later date. OK all right yes truly appreciate senator Irvin what she was expressing because I've I've definitely heard this and I've actually experienced this so we're not personally but understand I've experienced so thank you thank you senator Irber and thank you Mr Chair.
▶ Play
Representative Beck you had a question? Yes thank you this kind of follows up on senator hickey's maybe one of his concerns but in a little different mix so a dru a drug like that you know has a $10,000 would we just how many would we get4 dos my my point is this if this drug requires refrigeration. are we putting it in a you know there are refrigeration systems that are backed up and have been a power loss do we ever consider like if you had 10 of these doses sitting in a in the personal fridge rather the power goes out now you've you so no I
▶ Play
mean they there would not be excess dosage that some is sitting at somebody's home I mean that you're going to look at probably getting refills on a monthly, you know if this is a every other week kind of dosage we're only going to give up to to pins that they would be storing and then they would go back the next month
▶ Play
and get the refill. right thank you right seeing no other questions I believe they exhibit B That would
▶ Play
Speaker 55 31:25
be lovely. Senator Irvin, would you
▶ Play
make your motion? Thank you Mr Chair. Yes, so I make a motion, to approve let's see, let's see B1 I will make a motion to approve all of B1 September 2026 EBharmacy's B2 yes I know but we have to approve B1 and B3 as is B2 would be without7,89. we already approved B one though you are I'm so sorry my my apologies. So B2 would be to approve with without7,8 and 9 included. right so we have a motion do we have a second
▶ Play
we have a motion in 2 any discussion if not all those in favor let it be known by I any opposed motion carries now we will move on to item number3 which is the medical drug recommendations
▶ Play
B three. All right. starting with B3, these are again disclaimer drugs that are administered in a clinical setting items one and two are new to market we're going to exclude as we await further studies item 3 and4 and 5 are all related to that disease state but we are items three and four are the biosimilar that we are looking to add item ive would be the name brand that we are going to exclude moving forward Item6 we're excluding as news to market and looking for ongoing studies on that one itemtem7 and 8 are related we are going to cover the item7 this one's new to market but is outperforming number 8 it takes fewer injections and has a better overall outcome for the patient item 9 and 10 these are adding on as new trials have shown better overall survival item 11 is a new to market cancer treating drug but it is already achieved the national cancer rating of category one and has obviously proven better outcomes and better overall survival rates so we're looking to add that one on and then item 12 is an Alzheimer's disease drug that we've been studying for quite a while and we are adding uminsule to our formulary as it aligns with Blue Cross their treatment criteria as well as it gives us just a little bit more controlled with fixed dosage does have the potential to stop after one year if the plaques have been cleared so be glad to pause and answer any questions related to these drugs members any questions if
▶ Play
not then I would entertain emotion to approve the recommendations have a motion have a second, any discussion? if not all those in favor would let it be known by I. any opposed motion carries seeing no other business sure
▶ Play
and maybe this is for the chairers for us to consider kind of based on the conversation right here and and kind of what senator Love had had brought up u would would you all mind kind of giving us a a breakdown over the last year or the last two years that how much you know with some of these drugs how much of it has went bad? how many of you have had to come back and get and I don't know if we should start should look at and consider that maybe there's a cost cap on how much we'll allow allow per month before it needs to go to a clinical setting some of these things and I assume we had never would but and I see some of them that you're turning down you're talking about you know 140,000 per dose. I assume there's going to be at some point where we would not allow those to be administered or kept at the house but I just want to know what the cutoff is. The one that we were just discussing with that number one that's $20,000 a month. Is that our cap or is it fi0 or is it 100 or what do we have any type of cap in
▶ Play
place so it it's not necessarily really a a financial cap we are following FDA kind of recommendations and guidelines as we look and and that's when it comes through is when there's new guidelines issued or or new formulations that kind of go through all of those review and approval processes that's really what is driving whether it's kind of in that home or appropriate for a home kind of kind of kind of setting but we definitely could kind of look and a evaluate what would be an appropriate kind of gauge on misuse and when we would need to remove that authorization or that approval for that particular member. I we can go back and study that I'm just not sure for our plan though if and and and I appreciate what
▶ Play
you said about the FDA I'm just not for sure for our plan that if we should look at and maybe the membership here doesn't agree that at some point if if if a drug is a certain dollar amount per month again that maybe it should be administered in some type of clinical setting. maybe there's some time you know that you would look that there could be some exceptions on that with with the cost of some of these like I say I do worry because even the one that we're we're talking about we're talking about over 20,000 a month, you know for somebody to have and again maybe the committee doesn't agree with me on this and that's fine. I just at at least think it's worth the conversation to see if we should put something like that in. sir thank you Senator Boyd, do
▶ Play
you recognize thank you Mr Chair Mr Wallace this is not to disagree with Senator Hickey. This is again to try to add a little clarity if we're gonna look at hey is there a dollar amountu amount we're concerned about we would also want to look at what that might cost an administration fees or other things so that we just feel like we're making a good sound decision you know because the point is well taken, you know somebody loses $100,000 it's gonna take a lot of trips to the doctor to save $100,000 but also you know I know it's hard to go find a an example of one of these but they're they are hard to break but it could happen right so if you can help give the whole story that would be helpful to all of us thank you and just one last follow up on that in in some cases and and I
▶ Play
don't know in this situation we've been talking about mostly today it probably if if you can determine this it probably makes sense to do it via pharmacy like we're talking about because of the availability of the doctors or the clinics to to actually administer it so if if there's some problem in the system that says that for you know this doctor visit or this cancer treatment it's just easier or better or more timely because of that just any any kind of background so we could make a fully informed decision would be helpful Senator Irvin thank you. I
▶ Play
think it's a good conversation to have and that's one of the reasons why I asked about pill count, right? because if you have the ability to because a lot of these medications are expensive I mean even if they're not, I think a lot of times and we have done this on certain, you know, schedules of drugs to try to limit the amount of pills out there right? So for various reasons because they're being sold on the black market or whatever but you know it's a difference between I give myself a B1el injection shot every week, which I can administer with a syringe and a glass vial versa because it's not that expensive versus and I'm I'm referring to my father and so versus something that you know costs $11,000. Like I would have a heart attack with that were in my refrigerator because it might get lost or whatever you know. I think there is credibility to discuss this. I mean and and to try to figure out a way. I know specialty pharmacies my my dad's on a specialty pharmacy medication, you know and they call every single month and I have to authorize this and you know because we don't want something to be wasted. We don't want money to be wasted we don't want medication to be wasted or lost or misused or whatever. So I think it's a worthy conversation to have for sure and just to figure out what makes sense, you know what's common sense about it absolutely and
▶ Play
kind of to your point on kind of pill limits or anything like that. I mean a lot of the oncological drugs that are kind of coming in and being able to be administered outside of the clinical setting do have quantity limits do have half fills do have all of those kind of guidance that you've kind of mentioned in place so that we can control that cost so absolutely I I hear and and agree we'll give all the background and kind of be able to paint kind of a picture of what's going on
▶ Play
here no I appreciate it thanks that's a good
▶ Play
conversation. Thank you and and just to follow up because Senator Irvin brought up a good point. I was under the assumption that what we're talking about earlier was that it was administered at the pharmacy and they were maintaining it these are going picked up at the pharmacy and going home with them I assumed it was like the far the flu shot or or some of the other vaccinations these are actually going home. all right thank you for that
▶ Play
clarification and and just to clarify a little bit more because there are some that are being filled at a pharmacy location but then being sent over to a clinical provider for administration in that setting too so you've kind of got the three4 different kind of scenarios going on there good good conversation. right Senator Boyd you are recognized
▶ Play
for the last time you for
▶ Play
thank thank you Mr Chair so again to add to the conversation not detract from any other questions for the most part all of these medications we're talking about sending home the FDA has created an a package a way for where they've evaluated and said this is safe for the patient to self administer number 12, would you not agree that a physician or a nurse practitioner or a physician assistant someone with prescriptive authority has had the opportunity to evaluate whether or not that makes sense in that that case so if someone has significant Alzheimer's and they don't you know have a caregiver probably we're gonna bring them back we're gonna find a way to get them back to the clinic or what have you would you agree sir thank you for that clarity right
▶ Play
now seeing no other and having no other business before us we are adjourned
▶ Play

Agenda

A. Call to Order

0:17 - 0:23

B. Consideration for Review and Approval of Actions by the State Board of Finance

0:23 - 35:19 125 segments 16 speakers

The chair, Grant Wallace, presented a comprehensive set of September 2026 pharmacy formulary changes-including brand-to-generic switches, removal of prior-authorizations for members ≤ 25, addition of a new biosimilar, and exclusions for several high-cost or weight-loss drugs-covering items 1 through 24 and related notes on step-therapy and new market drugs.

Committee members questioned age-based authorization rules, grandfathering periods, and the safety and cost implications of self-administered high-price injections, leading Chair Petty to call for a motion to approve the pharmacy recommendations, which passed unanimously on an aye vote.

Subsequent motions to approve Exhibit B items were made, with Senator Irvin moving to adopt B1 (Sept 2026) and a modified B2 excluding items 7-9, and later a motion to adopt the medical drug recommendations (B3); both motions were seconded, passed without opposition, and recorded as approved.

C. Other Business

35:19 - 44:22 25 segments 5 speakers

Senator Hickey raised concerns about the lack of cost caps for very expensive self-administered drugs and suggested limits, while the chair explained that the plan follows FDA guidance rather than set financial caps; other senators discussed pill-count controls and waste prevention, resulting in a substantive policy-focused discussion but no formal motion or vote.

D. Adjournment

Speakers

Senator Jim Petty Chair Unverified
22 segments
Chair Unverified
63 segments
Senator Justin Boyd Unverified
9 segments
Senator Jimmy Hickey, Jr Unverified
22 segments
Speaker 22
1 segment
Speaker 24
1 segment
Speaker 27
1 segment
Representative Jack Ladyman Unverified
1 segment
Speaker 36
1 segment
Speaker 45
1 segment
Senator Missy Irvin Unverified
22 segments
Speaker 25
1 segment
Speaker 81
1 segment
Senator Fredrick J. Love Unverified
4 segments
Speaker 15
1 segment
Representative Rick Beck Unverified
2 segments
Speaker 55
1 segment